Armin Ghobadi

Medicine & Life Sciences

1. Chimeric Antigen Receptors 100%
2. axicabtagene ciloleucel 96%
3. T-Lymphocytes 50%
4. Cell- and Tissue-Based Therapy 47%
5. B-Cell Lymphoma 44%
6. Cell Transplantation 42%
7. Precursor Cell Lymphoblastic Leukemia-Lymphoma 41%
8. CD19 Antigens 41%
9. Allogeneic Cells 40%
10. Transplants 39%
11. Cytokine Release Syndrome 30%
12. Stem Cell Transplantation 25%
13. Multiple Myeloma 24%
14. Therapeutics 21%
15. Survival 20%
16. Lymphoma 20%
17. GATA2 Deficiency 18%
18. Stem Cells 18%
19. Transplantation 17%
20. Tissue Donors 17%
21. Graft vs Host Disease 17%
22. Hematologic Neoplasms 16%
23. blinatumomab 15%
24. Hematopoietic Stem Cell Transplantation 15%
25. Acute Myeloid Leukemia 14%
26. Cytarabine 14%
27. Bendamustine Hydrochloride 13%
28. B-Lymphocytes 13%
29. Safety 13%
30. Progression-Free Survival 12%
31. Azacitidine 12%
32. Decitabine 11%
33. Neoplasms 11%
34. Bone Marrow 11%
35. Myelodysplastic Syndromes 10%
36. Tumor Burden 10%
37. Cyclophosphamide 10%
38. Expert Testimony 10%
39. Leukemia 10%
40. plerixafor octahydrochloride 10%
41. Neurotoxicity Syndromes 10%
42. Nervous System 9%
43. Non-Hodgkin's Lymphoma 9%
44. Granulocyte Colony-Stimulating Factor 9%
45. Etoposide 9%
46. Lymphoma, Large B-Cell, Diffuse 9%
47. Bortezomib 8%
48. Drug Therapy 8%
49. Transplant Recipients 8%
50. Dexamethasone 8%